A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancer-Reference-Cited by-同舟云学术

A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancer

Published:2016-09 Issue:9 Volume:27 Page:1712-1718
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Lacouture M.E.,Keefe D.M.,Sonis S.,Jatoi A.,Gernhardt D.,Wang T.,Doherty J.P.,Giri N.,Nadanaciva S.,O'Connell J.,Sbar E.,Piperdi B.,Garon E.B.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/27/9/1712/19446679/mdw227.pdf

Reference9 articles.

1. Dacomitinib for the treatment of advanced or metastatic non-small-cell lung cancer;Mok;Future Oncol,2014

2. Management of EGFR TKI-induced dermatologic adverse events;Melosky;Curr Oncol,2015

3. Management of diarrhea induced by epidermal growth factor receptor tyrosine kinase inhibitors;Hirsh;Curr Oncol,2014

4. Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness;Chren;J Invest Dermatol,1996

5. Reliability and validity of a patient self-administered daily questionnaire to assess impact of oral mucositis (OM) on pain and daily functioning in patients undergoing autologous hematopoietic stem cell transplantation (HSCT);Stiff;Bone Marrow Transplant,2006

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Impact of Dermatologic Adverse Events on the Quality of Life of Oncology Patients: A Review of the Literature;American Journal of Clinical Dermatology;2024-02-16

2. Effects of H2-Receptor Antagonists on the Exposure of Dacomitinib;Pharmaceutics;2024-01-17

3. Protein Kinase Inhibitors Indicated for Lung Cancer: Pharmacodynamics, Pharmacokinetics, Adverse Drug Reactions, and Evaluation in Clinical Trials;Journal of Clinical Pharmacy and Therapeutics;2024-01

4. A Systematic Review of Literatures: To Identify Non-Cancer Drugs Repurposed for Lung Cancer;2023-12-04

5. Traditional Chinese Medicine Formulae QY305 Reducing Cutaneous Adverse Reaction and Diarrhea by its Nanostructure;Advanced Science;2023-12-03